|
1
|
Roden AC: Evolution of classification of
thymic epithelial tumors in the Era of Dr Thomas V. Colby. Arch
Pathol Lab Med. 141:232–246. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to The 2015 World Health
Organization classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du J and Zhou XJ: Precise diagnosis and
treatment of thymic epithelial tumors based on molecular
biomarkers. Crit Rev Oncog. 22:507–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamanaka K, Koyama T, Matsuoka S, Takeda
T, Miura K, Yamada K, Hyogotani A, Seto T, Okada K and Ito KI:
Analysis of surgical treatment of Masaoka stage III–IV thymic
epithelial tumors. Gen Thorac Cardiovasc Surg. 66:731–735. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shapiro M and Korst RJ: Surgical
approaches for Stage IVA thymic epithelial tumors. Front Oncol.
3:3322014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Du Y and Wang Y, Tang J, Ge J, Qin Q,
Jiang LI, Liu X, Zhu X and Wang Y: Pancreatic metastasis resulting
from thymic neuroendocrine carcinoma: A case report. Oncol Lett.
11:1907–1910. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khandelwal A, Sholl LM, Araki T, Ramaiya
NH, Hatabu H and Nishino M: Patterns of metastasis and recurrence
in thymic epithelial tumours: Longitudinal imaging review in
correlation with histological subtypes. Clin Radiol. 71:1010–1017.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fischer SEJ: RNA interference and
microRNA-mediated silencing. Curr Protoc Mol Biol. 112:26 1.1–26. 1
5. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cesana M, Cacchiarelli D, Legnini I,
Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A
long noncoding RNA controls muscle differentiation by functioning
as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB,
Yin DD, Kong R, Xia R, Lu KH, Li JH, et al: Lnc RNA HOTAIR
functions as a competing endogenous RNA to regulate HER2 expression
by sponging miR-331-3p in gastric cancer. Mol Cancer. 13:922014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye S, Yang L, Zhao X, Song W, Wang W and
Zheng S: Bioinformatics method to predict two regulation mechanism:
TF-miRNA-mRNA and lncRNA-miRNA-mRNA in pancreatic cancer. Cell
Biochem Biophys. 70:1849–1858. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berrondo C, Flax J, Kucherov V, Siebert A,
Osinski T, Rosenberg A, Fucile C, Richheimer S and Beckham CJ:
Expression of the long non-coding RNA HOTAIR correlates with
disease progression in bladder cancer and is contained in bladder
cancer patient urinary exosomes. PLoS One. 11:e01472362016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao B, Zhang W, Chen L, Hang J, Wang L,
Zhang R, Liao Y, Chen J, Ma Q, Sun Z and Li L: Analysis of the
miRNA-mRNA-lncRNA network in human estrogen receptor-positive and
estrogen receptor-negative breast cancer based on TCGA data. Gene.
658:28–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giaccone G, Kim C, Thompson J, McGuire C,
Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan
MT, et al: Pembrolizumab in patients with thymic carcinoma: A
single-arm, single-centre, phase 2 study. Lancet Oncol. 19:347–355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Xu L, Du T, Gao Y, Wu Z and Luo D:
A nomogram predicting recurrence and guiding adjuvant radiation for
thymic carcinoma after resection. Ann Thorac Surg. 106:257–263.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu Z and Li Y, Takwi A, Li B, Zhang J,
Conklin DJ, Young KH, Martin R and Li Y: miR-301a as an NF-kappaB
activator in pancreatic cancer cells. EMBO J. 30:57–67. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peng Y, Zhang X, Ma Q, Yan R, Qin Y, Zhao
Y, Cheng Y, Yang M, Wang Q, Feng X, et al: MiRNA-194 activates the
Wnt/β-catenin signaling pathway in gastric cancer by targeting the
negative Wnt regulator, SUFU. Cancer Lett. 385:117–127. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bellissimo T, Ganci F, Gallo E, Sacconi A,
Tito C, De Angelis L, Pulito C, Masciarelli S, Diso D, Anile M, et
al: Thymic epithelial tumors phenotype relies on miR-145-5p
epigenetic regulation. Mol Cancer. 16:882017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bellissimo T, Russo E, Ganci F, Vico C,
Sacconi A, Longo F, Vitolo D, Anile M, Disio D, Marino M, et al:
Circulating miR-21-5p and miR-148a-3p as emerging non-invasive
biomarkers in thymic epithelial tumors. Cancer Biol Ther. 17:79–82.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo D, Ye Y, Qi J, Xu L, Zhang L, Tan X,
Tan Z, Yu X, Zhang Y, Ma Y and Li Y: MicroRNA-195a-5p inhibits
mouse medullary thymic epithelial cells proliferation by directly
targeting Smad7. Acta Biochim Biophys Sin (Shanghai). 48:290–297.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Enkner F, Pichlhofer B, Zaharie AT, Krunic
M, Holper TM, Janik S, Moser B, Schlangen K, Neudert B, Walter K,
et al: Molecular profiling of thymoma and thymic carcinoma: Genetic
differences and potential novel therapeutic targets. Pathol Oncol
Res. 23:551–564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen M and Liu LX: miR-525-5p repressed
metastasis and anoikis resistance in cervical cancer via Blocking
UBE2C/ZEB1/2 Signal Axis. Dig Dis Sci. 65:2442–2451. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qi L, Gao C, Feng F, Zhang T, Yao Y, Wang
X, Liu C, Li J, Li J and Sun C: MicroRNAs associated with lung
squamous cell carcinoma: New prognostic biomarkers and therapeutic
targets. J Cell Biochem. 120:18956–18966. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang HY and Wang ZJ: ADPGK-AS1 promotes
the progression of colorectal cancer via sponging miR-525 to
upregulate FUT1. Eur Rev Med Pharmacol Sci. 24:2380–2386.
2020.PubMed/NCBI
|
|
31
|
Chang H, Zhang X, Li B and Meng X:
MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation
and migration in ovarian cancer through targeting miR-525-5p/MXD1
axis. Cancer Med. 9:6377–6386. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cybula M, Wieteska L,
Jozefowicz-Korczynska M, Karbownik MS, Grzelczyk WL and Szemraj J:
New miRNA expression abnormalities in laryngeal squamous cell
carcinoma. Cancer Biomark. 16:559–568. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Starenki D, Sosonkina N, Hong SK, Lloyd RV
and Park JI: Mortalin (GRP75/HSPA9) promotes survival and
proliferation of thyroid carcinoma cells. Int J Mol Sci.
20:20692019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Peng C, Yang P, Cui Y, He M, Liang L and
Di Y: HSPA9 overexpression inhibits apoptin-induced apoptosis in
the HepG2 cell line. Oncol Rep. 29:2431–2437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hou S, Shan M, Gao C, Feng X, Yang Y,
Zhang R, He Y, Zhang G and Zhang L: PCDHGB7 increases
chemosensitivity to carboplatin by inhibiting HSPA9 via inducing
apoptosis in breast cancer. Dis Markers. 2019:61315482019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi
Y and Guo J: Long noncoding RNA associated-competing endogenous
RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu J, Li Y, Lu J, Pan T, Ding N, Wang Z,
Shao T, Zhang J, Wang L and Li X: The mRNA related ceRNA-ceRNA
landscape and significance across 20 major cancer types. Nucleic
Acids Res. 43:8169–8182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo Z, Li Y, Liu X, Luo M, Xu L, Luo Y,
Xiao B and Yang H: Systems biology of myasthenia gravis,
integration of aberrant lncRNA and mRNA expression changes. BMC Med
Genomics. 8:132015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kong X, Wang J, Cao Y, Zhang H, Lu X, Wang
Y, Bo C, Wang T, Li S, Tian K, et al: The long noncoding RNA
MALAT-1 functions as a competing endogenous RNA to regulate MSL2
expression by sponging miR-338-3p in myasthenia gravis. J Cell
Biochem. 120:5542–5550. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang H, Li L and Yin L: Silencing LncRNA
LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma
via NF-ĸB pathway. Biochem Biophys Res Commun. 500:518–524. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gao R, Zhang R, Zhang C, Liang Y and Tang
W: LncRNA LOXL1-AS1 promotes the proliferation and metastasis of
medulloblastoma by activating the PI3K/AKT pathway. Anal Cell
Pathol (Amst). 2018:92756852018.PubMed/NCBI
|
|
42
|
Chen S, Li W and Guo A: LOXL1-AS1 predicts
poor prognosis and promotes cell proliferation, migration, and
invasion in osteosarcoma. Biosci Rep. 39:BSR201904472019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun Q, Li J, Li F, Li H, Bei S, Zhang X
and Feng L: LncRNA LOXL1-AS1 facilitates the tumorigenesis and
stemness of gastric carcinoma via regulation of miR-708-5p/USF1
pathway. Cell Prolif. 52:e126872019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bai T, Liu Y and Li B: LncRNA
LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the
doxorubicin resistance of prostate cancer DU-145 cells. IUBMB life.
71:1537–1551. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang B, Zhou M, Zou L, Miao J, Wang Y, Li
Y, Lu S and Yu J: Long non-coding RNA LOXL1-AS1 acts as a ceRNA for
miR-324-3p to contribute to cholangiocarcinoma progression via
modulation of ATP-binding cassette transporter A1. Biochem Biophys
Res Commun. 513:827–833. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Long B, Li N, Xu XX, Li XX, Xu XJ, Liu JY
and Wu ZH: Long noncoding RNA LOXL1-AS1 regulates prostate cancer
cell proliferation and cell cycle progression through miR-541-3p
and CCND1. Biochem Biophys Res Commun. 505:561–568. 2018.
View Article : Google Scholar : PubMed/NCBI
|
